Ajanta Pharma zooms 8% to fresh 52-week high on strong Q3 results

Despite normalisation in fixed costs (at pre-Covid levels), the company's Ebitda margin came 372 bps higher YoY at 32 per cent, driven by improvement in gross margin

Shares of Ajanta Pharma rallied 8 per cent to a fresh 52-week high of Rs 1,879.45 on the BSE on Wednesday after reporting a 64 per cent rise in its consolidated net profit to Rs 177 crore for the quarter ended December 2021, mainly on account of robust sales. 

Consolidated revenue from operations of the company stood at Rs 749 crore for the quarter under consideration. It was Rs 651 crore for the same period a year ago, the company said in a BSE filing.

Besides, despite normalisation in fixed costs (at pre-Covid levels), Ebitda margin came 372 basis points (bps) higher